Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

• Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - "These encouraging data demonstrate that DYNE-302 exhibited prolonged activity in preclinical FSHD models, highlighting our innovative approach to targeting the genetic cause of this devastating and progressive muscle disease with no currently approved therapies," said Oxana Beskrovnaya, Ph.D., chief scientific officer of Dyne. "Additionally, the findings presented toda ...